Announced Tue, 18 Aug · 17:24 IST
Alivus to acquire 76 percent stake in IQGEN-X Pharma for about Rs 9.12 cr
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹1400.00
prior close
₹1398.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+0.7+0.6+0.8-2.4-3.1————————
Up moveDown movePending
AI summary
Alivus Life Sciences board approved acquiring 76 percent stake (8,60,589 shares) in IQGEN-X Pharma for about Rs 9.12 crores in cash. IQGEN-X does formulation development of oral solids, sterile injectables and ophthalmic solutions. Its FY26 turnover was Rs 348 lacs, up from Rs 318 lacs in FY25. Deal expected to close by December 6, 2026. Alivus says the deal strengthens its API and CDMO offerings. Not a related party deal.
Likely market impact
Small tuck-in deal worth about Rs 9.12 cr that strengthens Alivus CDMO and API offerings. Modest size means limited near-term earnings impact, but supports long-term pharma services growth.